Your shopping cart is currently empty

Zevaquenabant ((S)-MRI-1867), a dual cannabinoid CB1 receptor and inducible NOS (iNOS) antagonist, is orally bioavailable and peripherally restricted. It effectively mitigates obesity-induced chronic kidney disease (CKD).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $970 | Inquiry | Inquiry |
| Description | Zevaquenabant ((S)-MRI-1867), a dual cannabinoid CB1 receptor and inducible NOS (iNOS) antagonist, is orally bioavailable and peripherally restricted. It effectively mitigates obesity-induced chronic kidney disease (CKD). |
| In vitro | Zevaquenabant simultaneously inhibits CB1 receptors and iNOS in peripheral organs [1]. |
| In vivo | Zevaquenabant (3 mg/kg; p.o.; for 28 days) significantly enhances renal morphology and function in diet-induced obese mice[1]. Using 6-week-old male C57Bl/6J mice as an animal model for diet-induced obesity[1], the administration of Zevaquenabant markedly improved kidney health and performance. |
| Synonyms | (S)-MRI-1867 |
| Molecular Weight | 547.98 |
| Formula | C25H21ClF3N5O2S |
| Cas No. | 1998760-00-1 |
| Smiles | CC(=N)N=C(NS(=O)(=O)c1ccc(cc1)C(F)(F)F)N1C[C@@H](C(=N1)c1ccc(Cl)cc1)c1ccccc1 |w:3.2,c:23| |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.